ArticleDiabetes, obesity & metabolism2022

Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.

Odette S Reifsnider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.